<DOC>
	<DOCNO>NCT00245089</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vincristine , dactinomycin , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give vincristine , dactinomycin , cyclophosphamide together work treat patient embryonal rhabdomyosarcoma .</brief_summary>
	<brief_title>Vincristine , Dactinomycin , Cyclophosphamide Treating Patients With Embryonal Rhabdomyosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free survival rate patient low-risk embryonal rhabdomyosarcoma treat intensive chemotherapy comprise vincristine , dactinomycin , cyclophosphamide follow vincristine dactinomycin . OUTLINE : Patients receive vincristine IV , dactinomycin IV , cyclophosphamide IV day 1 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . Patients receive vincristine IV dactinomycin IV day 1 . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 41 patient accrue study .</detailed_description>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis embryonal rhabdomyosarcoma Primary operation pathological diagnosis within past 42 day The following variant eligible : Botryoid Spindle cell Anaplastic Meets 1 follow stage criterion : Stage I , clinical group II ( N1 ) Favorable site Any tumor size Microscopic residual disease Lymph nod clinically positive Stage I , clinical group III ( N1 ) Favorable site ( orbit ) Any tumor size Gross residual disease Lymph nod clinically positive Stage I , clinical group III ( N0 , NX , N1 ) Favorable site ( except orbit ) Any tumor size Gross residual disease Lymph nod clinically negative , involvement unknown , positive Stage II , clinical group II ( N0 , NX ) Unfavorable site Small tumor ( ≤ 5 cm diameter ) Microscopic residual disease Stage III , clinical group I II ( N0 , NX , N1 ) Unfavorable site Small tumor ( ≤ 5 cm diameter ) positive node large tumor ( &gt; 5 cm diameter ) lymph node status Completely resect microscopic residual disease PATIENT CHARACTERISTICS : Performance status 03 Life expectancy Not specify Hematopoietic WBC ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 7.5 g/dL Hepatic SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 2.5 time ULN Bile acid ≤ 2.5 time ULN Renal Creatinine base age follow : ≤ 0.8 mg/dL ( patient &lt; 5 year age ) ≤ 1.2 mg/dL ( patient 59 year age ) ≤ 1.5 mg/dL ( patient ≥ 10 year age ) Cardiovascular No severe heart disease Other Not pregnant nursing No uncontrolled infection Must acceptable organ function age No malignancy within past 5 year No hypersensitivity attribute study drug No CharcotMarieTooth disease chickenpox PRIOR CONCURRENT THERAPY : Chemotherapy No prior anticancer chemotherapy Endocrine therapy Prior anticancer steroid allow Radiotherapy Prior emergency radiotherapy allow within past 2 week Other No concurrent pentostatin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
</DOC>